Drata

NOVEMBER 17, 2026

Compliance Gap Blocking Every New Revenue Partnership

A 30-person medical device startup building an AI-powered diagnostic system had a hard commercial ceiling: health centers, clinics, and insurance payers were requiring SOC 2 and HIPAA compliance evidence before signing or renewing contracts. Without attestation artifacts, every active partnership conversation was stalled. The company needed a compliance posture it could present to revenue partners immediately, not after a months-long evaluation. It closed a full SOC 2 and HIPAA monitoring program in 9 days.

[ The Problem ]

Partners Won't Sign Until You Can Prove Compliance. You Can't Prove What You Haven't Built.

For a medical device startup selling into health systems and insurance networks, compliance is not a back-office concern. It is a commercial prerequisite. Every new revenue partnership required SOC 2 and HIPAA evidence before contracts could execute. The company had neither.

The business consequence was direct: no attestation artifacts meant no new partnerships, and no new partnerships meant a hard ceiling on growth for a company at exactly the stage where commercial momentum matters most. The urgency was not theoretical. Active conversations with payers and clinical buyers were gated on credentials the company could not yet produce.

[ What they needed ]

The compliance initiative needed to accomplish several things at once:

  • Establish a SOC 2 and HIPAA monitoring program across a multi-cloud infrastructure stack
  • Produce attestation artifacts quickly enough to unblock active partner conversations
  • Evaluate bundled compliance platform and audit offerings against standalone alternatives
  • Assess the professional standards implications of using a single vendor for both platform and audit
  • Secure a path to formal audit completion without overcommitting budget at an early company stage
  • Address an emerging FDA requirement for penetration testing tied to an AI-powered product feature

[ Why Drata won ]

Selected over Thoropass, Drata won by reframing the bundled competitor's lower price as a professional standards risk rather than a savings opportunity.

  1. Auditor independence argument: Thoropass's bundled platform-plus-audit model was repositioned as an AICPA independence concern. For a company selling into regulated health system and insurance payer relationships, the argument that a single vendor providing both compliance monitoring and audit attestation introduces a professional ethics conflict was directly relevant and credible to this buyer.

  2. Immediate value before audit completion: The offer of a Day-1 Letter of Assertion and audit engagement letter gave the buyer something concrete to present to revenue partners right away. Thoropass's bundled model required waiting for the full process to complete before the buyer had anything to show.

  3. Budget structure matched the buyer's constraints: Rather than asking the buyer to choose between Drata and a lower-cost bundle, the offer was restructured to match the total budget by pairing the platform with a separately scoped audit engagement, preserving the methodology differentiation without requiring the buyer to spend more.

  4. Deferred audit payment model: Drata's approach of billing audit services as delivered, rather than requiring full upfront payment, was a meaningful cash flow advantage for an early-stage company managing a tight compliance budget.

[ How Drata solved it ]

Drata's GRC platform provided native continuous monitoring for SOC 2 and HIPAA across the company's AWS, GCP, Rippling, Jira, GitHub, and MongoDB Atlas stack with no custom engineering required. Coverage was immediate and comprehensive across the full infrastructure footprint.

Drata's AIQA capabilities gave the compliance team automated evidence collection and control monitoring from day one, removing the manual overhead that typically consumes early-stage compliance programs. Rather than waiting for audit completion to show partners something tangible, the team received a Day-1 Letter of Assertion and an audit engagement letter, giving them credible compliance documentation to present to revenue partners while the formal Type 2 process proceeded.

The audit was structured through a vetted audit partner, keeping the compliance platform and the audit function independent, which addressed a professional standards concern the team had raised about bundled alternatives. Drata's TPRM capabilities also opened a path to managing the third-party risk surface as the company's partner network grows.

[ Before and after Drata ]

Before Drata, every revenue partnership conversation was blocked by the absence of compliance credentials the company had no timeline to produce. After, a SOC 2 and HIPAA monitoring program was live within days of signing, an audit engagement was underway, and the compliance posture that had been a commercial ceiling became a presentable asset in active partner negotiations.

Before Drata
After Drata
Before DrataNo SOC 2 or HIPAA compliance posture. Health system and insurance payer contracts could not execute without attestation evidence the company could not produce.
After DrataSOC 2 and HIPAA continuous monitoring live across the full AWS, GCP, and Rippling stack. Compliance posture established and operational.
Before DrataActive revenue partnership conversations stalled. Missing compliance credentials were a hard gate on commercial growth.
After DrataRevenue partnership conversations unblocked. Compliance credentials now available to present to health center, clinic, and insurance payer partners.
Before DrataNo audit engagement in motion. Certification was a future intention with no defined timeline or deliverable.
After DrataSOC 2 audit engagement underway with a defined timeline. Certification is a scheduled deliverable, not an aspiration.
Before DrataCompliance program scope undefined. A mid-cycle stakeholder expanded requirements from SOC 2 only to include HIPAA, with no existing framework to absorb the change.
After DrataBoth SOC 2 and HIPAA frameworks in scope and monitored within a single platform. Scope expansion absorbed without additional evaluation cycles.
Before DrataNo path to presenting compliance credentials to partners before formal audit completion.
After DrataDay-1 Letter of Assertion and audit engagement letter in hand. Partners can receive compliance documentation immediately, ahead of Type 2 completion.

[ Business outcome ]

A startup that could not enter a partner conversation without a compliance gap now has a structured SOC 2 and HIPAA monitoring program in production and an audit engagement underway. Active revenue partnership conversations that were previously gated on missing compliance credentials are now unblocked.

The company moved from no compliance posture to a presentable attestation position in under two weeks, a timeline that matched the urgency of its commercial pipeline. The audit path is defined, scheduled, and tied to a clear business outcome: closing the partnerships that drive the next stage of growth. The compliance program is no longer a blocker. It is a commercial asset.

More Wins to Explore